文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

儿童脑型疟疾中DON的I/IIA期剂量递增安全性研究:临床试验方案

DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial.
PubMed 文献 · Trials · 2024-01-26

该I/IIA期剂量递增试验旨在评估谷氨酰胺拮抗剂DON单次静脉给药的安全性,先在健康成人及无并发症疟疾成人中开放标签递增剂量(0.1、1.0、5.0、10 mg/kg),随后在6个月至14岁脑型疟疾患儿中开展随机双盲安慰剂对照研究,并探索性评估DON的初步疗效。

要点

  • DON单次静脉给药在健康成人、无并发症疟疾成人及脑型疟疾患儿中评估安全性。
  • 成人部分开放标签,40例健康成人同期入组40例无并发症疟疾成人,每队列10例。
  • 儿童部分随机双盲安慰剂对照,入组72例6个月至14岁脑型疟疾患儿。

核心结论

  • 若结果支持DON的初步安全性和疗效,则后续将开展II期和III期临床试验。

研究设计与样本

  • I/IIA期剂量递增临床试验,单次静脉给予DON,主要评估安全性,次要目标评估药代动力学。
  • 开放标签成人部分入组40例健康成人和40例无并发症疟疾成人,每队列10例,剂量在队列间从0.1 mg/kg递增至1.0、5.0、10 mg/kg。
  • 随机双盲安慰剂对照儿童部分入组72例6个月至14岁脑型疟疾患儿,研究至少覆盖三个疟疾季节,计划在儿童入组达50%时进行中期分析。

主要发现

  • 儿童部分前一半受试者接受DON 0.1 mg/kg、1.0 mg/kg或安慰剂,后一半受试者的给药方案依据先前入组者的安全性和初步疗效结果确定。
  • 儿童部分设探索性结局,通过脑电图、磁共振成像和经颅多普勒在DON给药前后评估对脑型疟疾结局有预测价值的诊断指标。
  • 所有疟疾受试者均按当地指南接受标准抗疟治疗,不论研究药物剂量组别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite treatment with highly effective antimalarial drugs, malaria annually claims the lives of over half a million children under 5-years of age in sub-Saharan Africa. Cerebral malaria (CM), defined as Plasmodium falciparum infection with coma, is the severe malaria syndrome with the highest mortality. Studies in the CM mouse model suggest that a T cell-mediated response underlies CM pathology, opening a new target for therapy in humans. This trial aims to establish the preliminary safety of one such novel therapy, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON). METHODS: In this phase I/IIa dose-escalation clinical trial, a single dose of intravenous (IV) DON is administered to three participants groups-healthy adults and adults with uncomplicated malaria, then pediatric participants with CM-to primarily assess safety. The secondary objective of this trial is to assess pharmacokinetics of DON over a range of doses. The open-label adult portion of the trial enrolls 40 healthy adults concurrently with 40 adults with uncomplicated malaria. Cohorts of 10 participants receive a single IV dose of DON with doses escalating between cohorts from 0.1 mg/kg, 1.0 mg/kg, 5.0 mg/kg, to 10 mg/kg. Following subsequent safety review, a randomized, double-blind, and placebo-controlled pediatric study enrolls 72 participants aged 6 months to 14 years with CM. The pediatric portion of the study minimally spans three malaria seasons including a planned interim analysis after 50% of pediatric enrollments. The first half of pediatric participants receive DON 0.1 mg/kg, 1.0 mg/kg, or placebo. Dosing for the second half of pediatric participants is informed by the safety and preliminary efficacy results of those previously enrolled. The pediatric portion of the study has an exploratory outcome evaluating the preliminary efficacy of DON. Efficacy is assessed by diagnostics predictive of CM outcome: electroencephalography (EEG), magnetic resonance imaging (MRI), and transcranial doppler (TCD), measured before and after DON administration. All participants with malaria receive standard of care antimalarials in accordance with local guidelines, regardless of study drug dose group. DISCUSSION: This preliminary safety and efficacy study evaluates DON, a candidate adjunctive therapy for pediatric CM. If results support DON preliminary safety and efficacy, follow-up phase II and III clinical trials will be indicated. TRIAL REGISTRATION: This trial was registered on ClinicalTrials.gov on 28 July 2022 (NCT05478720).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nampota-Nkomba N, Nyirenda OM, Mallewa J, et al. DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial. Trials. 2024. PMID: 38279124. doi:10.1186/s13063-023-07808-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。